πŸ‡ΊπŸ‡Έ FDA
Patent

US 11634413

Neprilysin inhibitors

granted A61KA61K31/415A61K31/4192

Quick answer

US patent 11634413 (Neprilysin inhibitors) held by Theravance Biopharma R&D IP, LLC expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/415, A61K31/4192, A61K31/42, A61K31/421